TRT Monitoring: What Blood Tests You Need and Why

Testosterone Replacement Therapy (TRT) can be life-changing for men suffering from clinical hypogonadism. When administered correctly, it restores energy, improves cognitive function, rebuilds muscle mass, and enhances overall quality of life. However, TRT is a serious medical intervention, not a casual supplement. Introducing exogenous hormones into the body alters complex endocrine feedback loops and impacts multiple organ systems.

As a clinician, I emphasize to every patient that starting TRT is only the first step. The cornerstone of safe, effective, and sustainable therapy is rigorous, ongoing biochemical monitoring. Without regular blood testing, you are flying blind, risking severe side effects and suboptimal symptom relief.

The Core Monitoring Panel

Effective TRT management requires evaluating a specific set of biomarkers at regular intervals (typically 6 weeks, 3 months, 6 months, and then annually). Here is what we must monitor and why:

1. Total and Free Testosterone

The primary goal is to bring testosterone levels back into the optimal physiological range. We measure Total Testosterone to ensure the dosage is adequate, but more importantly, we calculate Free Testosterone (using SHBG). Free Testosterone is the active hormone driving symptom resolution. If Total Testosterone is high but SHBG is also very high, the patient may still experience symptoms of low testosterone, necessitating a protocol adjustment.

2. Oestradiol (E2)

The male body naturally converts a portion of testosterone into oestradiol via the aromatase enzyme. When you introduce exogenous testosterone, oestradiol levels inevitably rise. While men need oestrogen for bone and cardiovascular health, excessive levels can cause water retention, mood instability, erectile dysfunction, and gynecomastia. Monitoring E2 ensures the testosterone-to-oestrogen ratio remains balanced.

3. Haematocrit and Full Blood Count (FBC)

This is arguably the most critical safety marker in TRT. Testosterone stimulates the bone marrow to produce red blood cells (erythropoiesis). While this improves oxygen transport and stamina, excessive red blood cell production leads to polycythemia—a condition where the blood becomes abnormally thick and viscous. Elevated haematocrit significantly increases the risk of hypertension, thrombosis (blood clots), stroke, and cardiovascular events. Regular FBC monitoring is non-negotiable to ensure blood viscosity remains within safe limits.

4. Prostate-Specific Antigen (PSA)

Testosterone does not cause prostate cancer, but it can stimulate the growth of an existing, undiagnosed prostate cancer. Therefore, establishing a baseline PSA before starting TRT and monitoring it regularly is mandatory clinical practice. A significant or rapid rise in PSA while on TRT requires immediate urological investigation.

5. Liver and Kidney Function

While modern injectable and transdermal TRT preparations bypass the first-pass metabolism of the liver (unlike older oral forms), it is still essential to monitor comprehensive metabolic function. We assess liver enzymes (ALT, AST) and kidney markers (eGFR, Creatinine) to ensure the body is processing and clearing metabolites efficiently.

The Importance of Trough Testing

Timing is everything in TRT monitoring. Blood tests should generally be taken at the "trough"—the point when testosterone levels are at their lowest, immediately before your next scheduled dose or application. Trough testing provides the most accurate picture of your baseline exposure and helps clinicians determine if the dosage frequency needs adjustment to prevent hormonal peaks and valleys.

TRT is a highly individualized therapy. By committing to a structured monitoring protocol, you ensure that your treatment remains safe, optimized, and focused on long-term vitality.

Medical References

1. Bhasin, S., et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715-1744.
2. Osterberg, E. C., Bernie, A. M., & Ramasamy, R. (2014). Risks of testosterone replacement therapy in men. Indian Journal of Urology, 30(1), 2-7.
3. British Society for Sexual Medicine (BSSM). (2023). Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice.